Lv6
1840 积分 2021-12-10 加入
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial
26天前
已完结
Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer
1个月前
已完结
Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer
1个月前
已完结
Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial
1个月前
已完结
A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: The Keystone-001 trial
1个月前
已完结
Preclinical Assessment of the PI3Kα Selective Inhibitor Inavolisib and Prediction of Its Pharmacokinetics and Efficacious Dose in Human
2个月前
已完结
Emerging Roles for AKT Isoform Preference in Cancer Progression Pathways
4个月前
已完结
First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non–Hodgkin Lymphoma
4个月前
已完结
Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors
5个月前
已完结
ROS1-positive non-small cell lung cancer (NSCLC): biology, diagnostics, therapeutics and resistance
5个月前
已完结
皖公网安备34019202002308
